Drug Approval | May 01, 2025
Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
This approval authorizes the company to export Ibuprofen to the Chinese markets
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Delivers robust earnings performance, successfully navigating a dynamic environment
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Bayer expects 2025 to be the most difficult year of its turnaround
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
Subscribe To Our Newsletter & Stay Updated
